Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for levetiracetam
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levetiracetam or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on levetiracetam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Levetiracetam 500mg/5ml concentrate for infusion (Keppra) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb levetiracetam 500mg/5ml concentrate for infusion (Keppra Ò ) (No. 311/06) UCB Pharma Ltd Product Update 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission levetiracetam 500mg/5ml concentrate for infusion (Keppra Ò ) is accepted for use in NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. It is an alternative when oral administration is temporarily not feasible in patients for whom levetiracetam
Keppra (levetiracetam) Injection Drug Approval Package: Keppra (levetiracetam) NDA #021872 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Keppra (levetiracetam) Injection Company: UCB, Inc. Application No.: 021872 Approval Date: 07/31/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different
Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Sheehy O, St-Hillaire J M, Bernier G, Godfroid P, LeLorier J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of levetiracetam (LEV), a new antiepileptic agent, plus standard therapy (ST) for patients with refractory epilepsy. Three different dosage of levetiracetam were considered, 1,000 mg/day, 2,000 mg/day and 3,000 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study
Keppra (Levetiracetam) Oral Solution Drug Approval Package: Keppra (Levetiracetam) NDA #021505 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Keppra (Levetiracetam) Oral Solution Company: UCB Pharma Application No.: 021505 Approval Date: 7/15/2003 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: November 012004 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help
Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. BACKGROUND: The majority of patients with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug. However, up to 30% develop refractory seizures, particularly those with partial seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as an add-on treatment for drug-resistant localization related (partial (...) ) epilepsy. OBJECTIVES: To evaluate the effects of levetiracetam on seizures, side effects, quality of life and cognition, when used as an add-on treatment for patients with a drug-resistant localization related (partial) epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group trials register, the Cochrane Controlled Trials Register (Cochrane Library Issue 2, 2000). In addition, we contacted UCB SA (makers of levetiracetam) and experts in the field to seek any ongoing studies or unpublished
LevetiracetamLevetiracetamLevetiracetam Nash E, Sangha K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nash E, Sangha K. Levetiracetam. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs